● Recruiting

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)

Condition: Myeloproliferative Neoplasm · Essential Thrombocythemia · Primary Myelofibrosis, Prefibrotic Stage · Sponsor: University Hospital, Angers

PhaseNA

Planned participants260

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.

This description comes directly from the study's public registry record.

Talk to the study team

Laurane COTTIN, Doctor · +33 2 41 35 53 53 · Laurane.Cottin@chu-angers.fr

Emma BLANCHET · +33 2 41 35 63 38 · EmBlanchet@chu-angers.fr

Always discuss trial participation with your own doctor first.

Locations (10)

CHU Angers	Angers, France	Recruiting
Chu Bordeaux	Bordeaux, France	Recruiting
Chu Brest	Brest, France	Recruiting
Ch Cholet	Cholet, France	Recruiting
Ch Le Mans	Le Mans, France	Recruiting
Ch Morlaix	Morlaix, France	Recruiting
AP-HP Henri Mondor	Paris, France	Recruiting
Chu Poitiers	Poitiers, France	Recruiting
Ch Quimper	Quimper, France	Recruiting
Chu Tours	Tours, France	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04942080